YU7998A - Heterocyclic compounds and their pharmaceutic compositions - Google Patents

Heterocyclic compounds and their pharmaceutic compositions

Info

Publication number
YU7998A
YU7998A YU7998A YU7998A YU7998A YU 7998 A YU7998 A YU 7998A YU 7998 A YU7998 A YU 7998A YU 7998 A YU7998 A YU 7998A YU 7998 A YU7998 A YU 7998A
Authority
YU
Yugoslavia
Prior art keywords
heterocyclic compounds
pharmaceutic compositions
tiazoline
amiloid
etil
Prior art date
Application number
YU7998A
Other languages
Serbo-Croatian (sh)
Inventor
Eugene D. Thorsett
Warren J. Porter
Jeffrey S. Nissen
Lee H. Latimer
James E. Audia
James Droste
Original Assignee
Athena Neurosciences Inc.
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc., Eli Lilly And Company filed Critical Athena Neurosciences Inc.
Publication of YU7998A publication Critical patent/YU7998A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Compounds are described that inhibit the release of ß-amiloid peptides and/or their synthesis and accordingly they are used in treating Achaimer's disease. There are also described pharmaceutic compositions containing those new compounds inhibiting release ß-amiloid peptides and/or their synthesis, whereas those new compounds are, for example, (S)-5-( 1-N-(N-(3.5 difluorophenyl acetyl) - L-alaninin)amino)etil-3-etil- 1,2,4-oxadiazole, or (S)-2-(1-(3.5-difluorophenylacetamido-ethyl)-4-etoxycarbonyl-2-tiazoline,- or 4-(N-(S)-(1-metoxycarbonyl-1-phenyl)methyl) carbomoil-2-(3.5 difluorophenylmethyl)-2-tiazoline.
YU7998A 1997-02-28 1998-02-27 Heterocyclic compounds and their pharmaceutic compositions YU7998A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80826397A 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
YU7998A true YU7998A (en) 2002-06-19

Family

ID=25198310

Family Applications (1)

Application Number Title Priority Date Filing Date
YU7998A YU7998A (en) 1997-02-28 1998-02-27 Heterocyclic compounds and their pharmaceutic compositions

Country Status (22)

Country Link
EP (1) EP0968198A1 (en)
JP (1) JP2001513107A (en)
KR (1) KR20000075767A (en)
CN (1) CN1253554A (en)
AR (1) AR011164A1 (en)
AU (1) AU6662298A (en)
BR (1) BR9807876A (en)
CA (1) CA2278674A1 (en)
CO (1) CO4920244A1 (en)
EA (1) EA199900778A1 (en)
HR (1) HRP980093A2 (en)
HU (1) HUP0001293A3 (en)
ID (1) ID22873A (en)
IL (1) IL130851A0 (en)
NO (1) NO994016L (en)
NZ (1) NZ336613A (en)
PE (1) PE59399A1 (en)
PL (1) PL335424A1 (en)
TR (1) TR199902071T2 (en)
WO (1) WO1998038177A1 (en)
YU (1) YU7998A (en)
ZA (1) ZA981627B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
HUP0100294A3 (en) * 1997-12-22 2003-04-28 Lilly Co Eli Polycyclic alpha-amino-sigma-caprolactams and related compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
JP2002518481A (en) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド Compounds for inhibiting the release of β-amyloid peptide and / or its synthesis
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US7160880B1 (en) 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911803D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
MXPA02001340A (en) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Novel 1,4-benzodiazepine compounds and derivatives thereof.
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
CN1386118A (en) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 Lactams substituted by cyclic succinates as inhibitors of A beta protein production
DE10029077A1 (en) * 2000-06-13 2001-12-20 Bayer Ag New heterocyclic-substituted thiazole derivatives, useful as total or selective herbicides, insecticides, acaricides, nematocides, ectoparasiticides or antifouling agents
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
FR2840899B1 (en) * 2002-06-12 2005-02-25 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
AR039059A1 (en) 2001-08-06 2005-02-09 Sanofi Aventis COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS
KR20050010826A (en) 2002-06-05 2005-01-28 가부시키가이샤 가네카 Process for Producing Optically Active α-Methylcysteine Derivative
NZ588431A (en) 2004-09-17 2012-02-24 Whitehead Biomedical Inst Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
WO2008042928A2 (en) 2006-10-03 2008-04-10 Array Biopharma, Inc. Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
ES2700613T3 (en) * 2008-07-16 2019-02-18 Bitop Ag Synthesis of cyclic amidines
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CN103435549A (en) * 2013-08-14 2013-12-11 无锡惠飞生物医药技术有限公司 5-methyl-7-amino-5H,7H-dibenzo[b,d]azepin-6-ketone preparation method
CN105646208B (en) * 2016-02-24 2018-10-16 潍坊晶润化工股份有限公司 The preparation method of methyl pyruvate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2221684A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof

Also Published As

Publication number Publication date
ZA981627B (en) 1999-10-05
PL335424A1 (en) 2000-04-25
HRP980093A2 (en) 1998-12-31
AU6662298A (en) 1998-09-18
HUP0001293A1 (en) 2000-08-28
NZ336613A (en) 2001-10-26
JP2001513107A (en) 2001-08-28
HUP0001293A3 (en) 2000-09-28
NO994016L (en) 1999-10-18
TR199902071T2 (en) 2000-01-21
KR20000075767A (en) 2000-12-26
WO1998038177A1 (en) 1998-09-03
EP0968198A1 (en) 2000-01-05
NO994016D0 (en) 1999-08-19
ID22873A (en) 1999-12-16
CA2278674A1 (en) 1998-09-03
BR9807876A (en) 2000-02-29
IL130851A0 (en) 2001-01-28
PE59399A1 (en) 1999-06-21
AR011164A1 (en) 2000-08-02
CN1253554A (en) 2000-05-17
EA199900778A1 (en) 2000-04-24
CO4920244A1 (en) 2000-05-29

Similar Documents

Publication Publication Date Title
YU7998A (en) Heterocyclic compounds and their pharmaceutic compositions
IL108943A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
BR9714358A (en) Derivatives of n- (aryl / heteroaryl) amino acid, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds
TW279166B (en)
BR9908332A (en) Derivatives of n- [carbonyl (di-ring or substituted five-membered di-unsaturated triaza)] guanidine derivatives for the treatment of schistosomiasis
PT741716E (en) ANALOGOS OF DELTA 12,13-ISO-TAXOL ITS ANTI-NEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AR017219A1 (en) IMIDAZOL DERIVATIVES 1,4,5 SUBSTITUTES, COMPOSITIONS THAT INCLUDE THEM, PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES, USE OF DERIVATIVES TO MANUFACTURE OF A MEDICINAL PRODUCT
IL106777A (en) Monohydrate of 5-(2-(4-(1, 2-benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6- chloro-1, 3-dihydro-2h- indole-2-one hydrochloride and pharmaceutical compositions comprising it
ATE269312T1 (en) N-(AMIDINOPHENYL)-N'-(NOUN)-3H-2,4-BENZODIAZEPINE-3-ONE DERIVATIVES AS FACTOR XA INHIBITORS
TR199901653T2 (en) Phthalazinones.
ATE212991T1 (en) THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE DERIVATIVES WITH ANTIDIABETIC, HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE PROPERTIES
NO984470L (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
NZ315184A (en) Use of fluconazole for inhibiting the growth of cancers and viral infections
IL105989A (en) N-substituted azabicycloheptane derivatives and pharmaceutical compositions containing them
MY120156A (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide
NO971997D0 (en) Use of immunomodulatory agents
HUT73231A (en) Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis
GR3023427T3 (en) Heteroarylmethylbenzols aromatase inhibitors
ATE141248T1 (en) NEW BIS-PHENYL WITCHES
NO972435L (en) 2- (2,3,5,6-Tetrafluoro-4-pyridyl) -1,2,5-tradiazolidin-3-one 1,1-dioxides and preparations and methods of use thereof
IL85640A0 (en) 1-(1-aryl-2-hydroxyethyl)-imidazoles and salts thereof,processes for the preparation thereof and pharmaceutical compositions containing them
NO972450L (en) Substituted 2- (phosphinyloxymethyl) -1,2,5-thiadiazolidin-3-one 1,1-dioxides and preparations and method of use thereof
HUP9801761A3 (en) Fumarate salt of (r)-5-(methylaminosulphonyl-methyl)-3-(n-methylpyrrolidin-2-ylmethyl)-1h-indole, preparation and use thereof and pharmaceutical composition containing this compound
IL114239A0 (en) Pyrrolidine derivatives their preparation and com¦ositions containing them